Breakthrough: Crinetics' Once-Daily Oral PALSONIFY Matches Injectable Treatments in 96-Week Acromegaly Study

Crinetics reveals new data from acromegaly therapy programme

Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an oral treatment for acromegaly.The post Crinetics reveals new data from acromegaly therapy programme appeared first on Clinical Trials Arena.

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025

July 13, 2025 17:45 ET  | Source: Crinetics Pharmaceuticals, Inc. Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies Additional PALSONIFY presentations demonstrate reductions in patient-reported symptom burden, including both symptom severity and rates of symptom flares SAN DIEGO, July 13, […] The post Crinetics to Present New Long-Te…

Breakthrough: Crinetics' Once-Daily Oral PALSONIFY Matches Injectable Treatments in 96-Week Acromegaly Study

New long-term data reveals PALSONIFY maintains stable IGF-1 control with 91% patient retention, potentially replacing monthly injections. See full efficacy results.